{"id":152525,"date":"2026-08-25T20:31:15","date_gmt":"2026-08-25T20:31:15","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/152525\/"},"modified":"2026-08-25T20:31:15","modified_gmt":"2026-08-25T20:31:15","slug":"novo-nordisk-cpsenovo-b-reaches-lx9851-obesity-drug-milestone","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/152525\/","title":{"rendered":"Novo Nordisk (CPSE:NOVO B) Reaches LX9851 Obesity Drug Milestone"},"content":{"rendered":"\n

Track your investments for FREE<\/a> with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. <\/p>\n

Novo Nordisk (CPSE:NOVO B) and Lexicon Pharmaceuticals reached a key milestone in the development of first in class oral obesity drug LX9851. <\/p>\n

Lexicon received a milestone payment from Novo Nordisk tied to clinical progress for LX9851 in obesity and metabolic disorders. <\/p>\n

The advancement of LX9851 adds a new mechanism of action to Novo Nordisk’s obesity pipeline alongside its existing treatments. <\/p>\n

The update underscores ongoing efforts to address obesity as a major global health challenge with next generation therapies. <\/p>\n

For a wider view on how healthcare companies are using new tools and data driven approaches, explore 131 healthcare AI stocks<\/a>. <\/p>\n

\"CPSE:NOVO<\/a> CPSE:NOVO B Earnings & Revenue Growth as at Aug 2026 <\/p>\n

Novo Nordisk, a pharmaceuticals company with a DKK1.3 trillion market cap, focuses on researching, developing, manufacturing, and distributing treatments in areas such as obesity and metabolic disorders, so LX9851 fits directly into its core therapeutic focus. For readers tracking how large drug makers expand in obesity care, this collaboration with Lexicon Pharmaceuticals highlights how Novo Nordisk is using external partnerships alongside internal research. <\/p>\n

We’ve flagged 2 risks for Novo Nordisk. See which could impact your investment.<\/a> <\/p>\n

How does LX9851 fit into Novo Nordisk’s obesity strategy? <\/p>\n

LX9851 adds an oral, non incretin mechanism alongside Novo Nordisk’s existing GLP 1 based obesity and diabetes treatments. For investors, it broadens the toolkit in a market where less than 1% of people with obesity are treated with branded medications, according to the Narrative data. This supports Novo Nordisk’s push to serve a wider share of that untreated population. <\/p>\n

Does this LX9851 progress change the Novo Nordisk Narrative? <\/p>\n

The progress on LX9851 leans into the Narrative theme that future returns will rely heavily on obesity pills while the company manages pipeline setbacks. It supports the catalyst around expanding metabolic disease treatments and product formats, which could help offset risks such as pricing pressure and patent expiry highlighted in the Narrative. <\/p>\n

If we take a look at the community Narrative for Novo Nordisk<\/a>, we can see how this news fits into the bigger investment story. <\/p>\n

What should investors watch next to judge if LX9851 is on track? <\/p>\n

The clearest early signal will be how LX9851 moves through later stage trials, particularly whether Novo Nordisk advances it into Phase 2 and outlines a timetable for obesity and metabolic disorder indications. Any future updates on dosing, tolerability and planned trial size will help investors judge how central LX9851 could become in the obesity portfolio. <\/p>\n

For the full picture including more risks and rewards, check out the complete Novo Nordisk analysis<\/a>. <\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. <\/p>\n

Companies discussed in this article include NOVO-B.CO<\/a>. <\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…\n","protected":false},"author":2,"featured_media":152526,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[13009,26431,1339,272],"class_list":["post-152525","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-diabetes-treatments","tag-lexicon-pharmaceuticals","tag-metabolic-disorders","tag-novo-nordisk"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117158050941598940","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/152525","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=152525"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/152525\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/152526"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=152525"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=152525"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=152525"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}